Use of fast-acting insulin aspart in insulin pump therapy in clinical practice

被引:36
|
作者
Evans, Mark [1 ,2 ]
Ceriello, Antonio [3 ,4 ,5 ,6 ]
Danne, Thomas [7 ]
De Block, Christophe [8 ]
DeVries, J. Hans [9 ,10 ]
Lind, Marcus [11 ,12 ]
Mathieu, Chantal [13 ]
Norgaard, Kirsten [14 ]
Renard, Eric [15 ,16 ]
Wilmot, Emma G. [17 ]
机构
[1] Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, Box 289 Addenbrookes Hosp,Hills Rd, Cambridge CB2 0QQ, England
[2] Univ Cambridge, Dept Med, Box 289 Addenbrookes Hosp,Hills Rd, Cambridge CB2 0QQ, England
[3] IRCCS MultiMed, Milan, Italy
[4] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[5] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain
[6] IRCCS MultiMed, Dept Cardiovasc & Metab Dis, Sesto San Giovanni, Italy
[7] Kinderkrankenhaus Bult, Diabet Zentrum Kinder & Jugendliche, Hannover, Germany
[8] Antwerp Univ Hosp, Dept Endocrinol Diabetol Metab, Edegem, Belgium
[9] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands
[10] Profil Inst Metab Res, Neuss, Germany
[11] Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden
[12] NU Hosp Grp, Dept Med, Trollhattan Uddevalla, Sweden
[13] Univ Hosp Leuven, Clin & Expt Endocrinol, Leuven, Belgium
[14] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[15] Univ Montpellier, Montpellier Univ Hosp, Dept Endocrinol, Diabet,Nutr,CNRS,INSERM, Montpellier, France
[16] Univ Montpellier, Inst Funct Genom, CNRS, INSERM, Montpellier, France
[17] Univ Hosp Derby & Burton NHS Fdn Trust, Derby, England
来源
DIABETES OBESITY & METABOLISM | 2019年 / 21卷 / 09期
关键词
CSII; insulin pump therapy; GLUCOSE CONTROL; HIGH-FAT; TYPE-1; BOLUS; CHILDREN; EXCURSIONS; INFUSION; DELIVERY; ADULTS; ADOLESCENTS;
D O I
10.1111/dom.13798
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the additional excipients niacinamide and L-arginine. The improved pharmacological profile and greater early glucose-lowering action of faster aspart compared with IAsp suggests that faster aspart may be advantageous for people with diabetes using continuous subcutaneous insulin infusion (CSII). The recent onset 5 trial was the first to evaluate the efficacy and safety of an ultra-fast-acting insulin in CSII therapy in a large number of participants with type 1 diabetes (T1D). Non-inferiority of faster aspart to IAsp in terms of change from baseline in HbA1c was confirmed, with an estimated treatment difference (ETD) of 0.09% (95% CI, 0.01; 0.17; P < 0.001 for non-inferiority [0.4% margin]). Faster aspart was superior to IAsp in terms of change from baseline in 1-hour post-prandial glucose (PPG) increment after a meal test (ETD [95% CI], -0.91 mmol/L [-1.43; -0.39]; P = 0.001), with statistically significant improvements also at 30 minutes and 2 hours. The overall rate of severe or blood glucose-confirmed hypoglycaemia was not statistically significantly different between treatments, with an estimated rate ratio of 1.00 (95% CI, 0.85; 1.16). A numerical imbalance in severe hypoglycaemic episodes between faster aspart and IAsp was seen in the treatment (21 vs 7) and the 4-week run-in periods (4 vs 0). Experience from clinical practice indicates that all pump settings should be reviewed when initiating faster aspart with CSII, and that the use of continuous glucose monitoring or flash glucose monitoring, along with a good understanding of meal content and bolus type, may also facilitate optimal use. This review summarizes the available clinical evidence for faster aspart administered via CSII and highlights practical considerations based on clinical experience that may help healthcare providers and individuals with T1D successfully initiate and adjust faster aspart with CSII.
引用
收藏
页码:2039 / 2047
页数:9
相关论文
共 50 条
  • [1] Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
    Marc Evans
    Mathew Wilkinson
    Angeliki Giannpolou
    [J]. Diabetes Therapy, 2019, 10 : 1793 - 1800
  • [2] Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
    Evans, Marc
    Wilkinson, Mathew
    Giannpolou, Angeliki
    [J]. DIABETES THERAPY, 2019, 10 (05) : 1793 - 1800
  • [3] A trial of fast-acting aspart insulin (FIASP) in insulin pumps
    Khan, A. K.
    Weston, P. W. Philip
    Brake, J. B.
    Lamen, L. L.
    Ndebu, J. N.
    Ord, C. O.
    [J]. DIABETIC MEDICINE, 2023, 40
  • [4] Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
    Dutta, Deep
    Mohindra, Ritin
    Mahajan, Kunal
    Sharma, Meha
    [J]. DIABETES & METABOLISM JOURNAL, 2023, 47 (01) : 72 - 81
  • [5] Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes
    Raskin, P
    Riis, A
    Guthrie, RA
    Jovanovic, L
    Leiter, L
    [J]. DIABETES CARE, 2000, 23 (05) : 583 - 588
  • [6] Fast-Acting Insulin Aspart Use with the MiniMedTM 670G System
    Hsu, Liana
    Buckingham, Bruce
    Basina, Marina
    Ekhlaspour, Laya
    von Eyben, Rie
    Wang, Justin
    Lal, Rayhan A.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (01) : 1 - 7
  • [7] Fast-Acting Insulin aspart (faster aspart) - Clinical Data on Application in Type 1 and 2 Diabetes
    Jaeckel, E.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (06): : 313 - 319
  • [8] FAST-ACTING INSULIN ASPART: A REVIEW OF ITS PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES AND THE CLINICAL CONSEQUENCES
    Haahr, Hanne
    Heise, Tim
    [J]. DIABETES MELLITUS, 2020, 23 (02): : 140 - 160
  • [9] Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences
    Haahr, Hanne
    Heise, Tim
    [J]. CLINICAL PHARMACOKINETICS, 2020, 59 (02) : 155 - 172
  • [10] Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences
    Hanne Haahr
    Tim Heise
    [J]. Clinical Pharmacokinetics, 2020, 59 : 155 - 172